24.97 USD
-0.19 (-0.76%)
24.97 USD
0 (0%)
APLS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of APLS get a neutral evaluation. Nothing too spectacular is happening here. APLS is growing strongly while it is still valued neutral. This is a good combination! These ratings could make APLS a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
APLS had positive earnings in the past year.
In the past year APLS had a positive cash flow from operations.
In the past 5 years APLS always reported negative net income.
In the past 5 years APLS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.25%, APLS belongs to the top of the industry, outperforming 90.57% of the companies in the same industry.
APLS's Return On Equity of 11.21% is amongst the best of the industry. APLS outperforms 93.21% of its industry peers.
APLS's Return On Invested Capital of 8.15% is amongst the best of the industry. APLS outperforms 93.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROIC | 8.15% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APLS has a better Profit Margin (4.43%) than 89.25% of its industry peers.
With an excellent Operating Margin value of 7.91%, APLS belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
APLS has a better Gross Margin (88.85%) than 90.75% of its industry peers.
APLS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
2. Health
2.1 Basic Checks
APLS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, APLS has more shares outstanding
Compared to 5 years ago, APLS has more shares outstanding
Compared to 1 year ago, APLS has an improved debt to assets ratio.
2.2 Solvency
APLS has an Altman-Z score of 0.99. This is a bad value and indicates that APLS is not financially healthy and even has some risk of bankruptcy.
APLS has a Altman-Z score of 0.99. This is in the better half of the industry: APLS outperforms 62.45% of its industry peers.
APLS has a debt to FCF ratio of 5.78. This is a neutral value as APLS would need 5.78 years to pay back of all of its debts.
The Debt to FCF ratio of APLS (5.78) is better than 91.70% of its industry peers.
APLS has a Debt/Equity ratio of 0.90. This is a neutral value indicating APLS is somewhat dependend on debt financing.
The Debt to Equity ratio of APLS (0.90) is worse than 75.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Altman-Z | 0.99 |
ROIC/WACC0.95
WACC8.59%
2.3 Liquidity
APLS has a Current Ratio of 3.54. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
APLS's Current ratio of 3.54 is in line compared to the rest of the industry. APLS outperforms 41.89% of its industry peers.
APLS has a Quick Ratio of 3.10. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of APLS (3.10) is worse than 60.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.40%, which is quite impressive.
The Revenue has grown by 42.11% in the past year. This is a very strong growth!
The Revenue has been growing by 127.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
3.2 Future
Based on estimates for the next years, APLS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.97% on average per year.
APLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.78% yearly.
EPS Next Y116.93%
EPS Next 2Y11.09%
EPS Next 3Y25.11%
EPS Next 5Y26.97%
Revenue Next Year28.73%
Revenue Next 2Y6.41%
Revenue Next 3Y10.9%
Revenue Next 5Y13.78%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
APLS is valuated quite expensively with a Price/Earnings ratio of 80.55.
APLS's Price/Earnings ratio is rather cheap when compared to the industry. APLS is cheaper than 89.81% of the companies in the same industry.
APLS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.92.
APLS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.55 | ||
| Fwd PE | N/A |
4.2 Price Multiples
APLS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. APLS is cheaper than 91.70% of the companies in the same industry.
93.40% of the companies in the same industry are more expensive than APLS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.18 | ||
| EV/EBITDA | 38.19 |
4.3 Compensation for Growth
APLS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APLS's earnings are expected to grow with 25.11% in the coming years.
PEG (NY)0.69
PEG (5Y)N/A
EPS Next 2Y11.09%
EPS Next 3Y25.11%
5. Dividend
5.1 Amount
No dividends for APLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
24.97
-0.19 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.54%
Inst Owner Change-5.86%
Ins Owners3.7%
Ins Owner Change-0.37%
Market Cap3.16B
Revenue(TTM)1.02B
Net Income(TTM)44.99M
Analysts77.86
Price Target36.24 (45.13%)
Short Float %15.1%
Short Ratio6.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.57%
Min EPS beat(2)31.03%
Max EPS beat(2)38.1%
EPS beat(4)3
Avg EPS beat(4)-1.49%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-4.2%
EPS beat(12)7
Avg EPS beat(12)-3.46%
EPS beat(16)7
Avg EPS beat(16)-4.53%
Revenue beat(2)1
Avg Revenue beat(2)1.69%
Min Revenue beat(2)-7.17%
Max Revenue beat(2)10.55%
Revenue beat(4)2
Avg Revenue beat(4)-1.99%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.73%
Revenue beat(12)7
Avg Revenue beat(12)7.96%
Revenue beat(16)10
Avg Revenue beat(16)42.21%
PT rev (1m)0%
PT rev (3m)-5.96%
EPS NQ rev (1m)-4.32%
EPS NQ rev (3m)-34.62%
EPS NY rev (1m)1105.89%
EPS NY rev (3m)146.34%
Revenue NQ rev (1m)-0.84%
Revenue NQ rev (3m)-6.75%
Revenue NY rev (1m)2.78%
Revenue NY rev (3m)5.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.55 | ||
| Fwd PE | N/A | ||
| P/S | 3.11 | ||
| P/FCF | 40.18 | ||
| P/OCF | 40.06 | ||
| P/B | 7.88 | ||
| P/tB | 7.88 | ||
| EV/EBITDA | 38.19 |
EPS(TTM)0.31
EY1.24%
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)0.62
FCFY2.49%
OCF(TTM)0.62
OCFY2.5%
SpS8.03
BVpS3.17
TBVpS3.17
PEG (NY)0.69
PEG (5Y)N/A
Graham Number4.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROCE | 10.32% | ||
| ROIC | 8.15% | ||
| ROICexc | 21.17% | ||
| ROICexgc | 21.17% | ||
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% | ||
| FCFM | 7.74% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score7
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Debt/EBITDA | 4.4 | ||
| Cap/Depr | 13.41% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 1.92 | ||
| Cash Conversion | 96.08% | ||
| Profit Quality | 174.81% | ||
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 0.99 |
F-Score7
WACC8.59%
ROIC/WACC0.95
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
EPS Next Y116.93%
EPS Next 2Y11.09%
EPS Next 3Y25.11%
EPS Next 5Y26.97%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
Revenue Next Year28.73%
Revenue Next 2Y6.41%
Revenue Next 3Y10.9%
Revenue Next 5Y13.78%
EBIT growth 1Y136%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145.42%
EBIT Next 3Y34.96%
EBIT Next 5Y33.37%
FCF growth 1Y112.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.37%
OCF growth 3YN/A
OCF growth 5YN/A
APELLIS PHARMACEUTICALS INC / APLS FAQ
Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to APLS.
Can you provide the valuation status for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.
What is the profitability of APLS stock?
APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 5 / 10.
What are the PE and PB ratios of APELLIS PHARMACEUTICALS INC (APLS) stock?
The Price/Earnings (PE) ratio for APELLIS PHARMACEUTICALS INC (APLS) is 80.55 and the Price/Book (PB) ratio is 7.88.